Equities analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to announce ($0.49) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Denali Therapeutics’ earnings. The lowest EPS estimate is ($0.67) and the highest is ($0.14). Denali Therapeutics posted earnings per share of $0.79 during the same quarter last year, which suggests a negative year over year growth rate of 162%. The company is scheduled to issue its next earnings results on Tuesday, March 10th.
On average, analysts expect that Denali Therapeutics will report full-year earnings of ($2.02) per share for the current fiscal year, with EPS estimates ranging from ($2.18) to ($1.65). For the next year, analysts anticipate that the firm will post earnings of ($2.37) per share, with EPS estimates ranging from ($3.09) to ($1.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Denali Therapeutics.
DNLI has been the subject of several research analyst reports. ValuEngine lowered Denali Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 28th. Zacks Investment Research raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Monday, January 13th. Goldman Sachs Group raised Denali Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $20.00 to $37.00 in a research note on Sunday, January 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Denali Therapeutics in a research note on Friday, December 20th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.86.
NASDAQ:DNLI opened at $25.42 on Friday. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -35.80 and a beta of 2.05. Denali Therapeutics has a 52-week low of $14.24 and a 52-week high of $30.41. The stock has a fifty day moving average of $21.72 and a 200 day moving average of $18.50. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.59 and a current ratio of 10.59.
In related news, CEO Ryan J. Watts sold 42,185 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $18.02, for a total value of $760,173.70. Following the transaction, the chief executive officer now directly owns 12,505 shares of the company’s stock, valued at approximately $225,340.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Carole Ho sold 3,464 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $20.01, for a total value of $69,314.64. The disclosure for this sale can be found here. In the last three months, insiders sold 93,054 shares of company stock valued at $1,695,673. 21.20% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in DNLI. Tower Research Capital LLC TRC lifted its position in Denali Therapeutics by 1,721.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,095 shares of the company’s stock valued at $32,000 after acquiring an additional 1,980 shares in the last quarter. Aigen Investment Management LP bought a new position in Denali Therapeutics in the 4th quarter valued at approximately $52,000. NumerixS Investment Technologies Inc lifted its position in Denali Therapeutics by 260.6% in the 4th quarter. NumerixS Investment Technologies Inc now owns 3,606 shares of the company’s stock valued at $63,000 after acquiring an additional 2,606 shares in the last quarter. Quantbot Technologies LP bought a new position in Denali Therapeutics in the 4th quarter valued at approximately $77,000. Finally, Patriot Financial Group Insurance Agency LLC lifted its position in Denali Therapeutics by 390.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 4,900 shares of the company’s stock valued at $85,000 after acquiring an additional 3,900 shares in the last quarter. 73.64% of the stock is currently owned by institutional investors and hedge funds.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Read More: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.